Overview

SECOTEX® (Tamsulosin Hydrochloride) Bioequivalence Study Brazil - Fed Admin

Status:
Completed
Trial end date:
2009-12-22
Target enrollment:
Participant gender:
Summary
It will be an open-label, randomized, laboratory-blind, crossover study with 02 treatments, 02 sequences, and 02 periods, in which the volunteers receive, in each period, the test formulation or the reference formulation, under fed conditions.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Tamsulosin